Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of molnupiravir in hospitalized adults with COVID-19
jRCT2031200404Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2021
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Molnupiravir with Placebo (2 arms). Primary endpoints: Time-to-sustained recovery, Participants with adverse events and 1 more. Started Mar 2021; status: completed.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031200404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200404.